. They used a two-step 'knock-in' targeting strategy to insert a stop codon in Brca1 exon 11. The genetic background of the mice determined the extent of embryonic lethality. Surviving mice homozygous for the truncated Brca1 allele developed tumours at high frequency (about 85%) at around 17 months of age. The tumour spectrum included lymphomas, sarcomas, and carcinomas, and histologically diverse breast carcinomas developed in some mutant mice. The authors speculate that the truncated Brca1 protein plays a role in the late stages of tumour progression.
